The purpose of this study is to learn about: * effects of living with COVID-19 and * how effective is nirmatrelvir-ritonavir in treating COVID-19. This is a study of two groups of COVID-19 patients in Taiwan. In Group 1 the below participants were included in the study: * Patients of all ages. * Patients who were confirmed to have COVID-19 infection between 01 January 2021 and 31 December 2021. * Cases of patients registered in the databases. In Group 2 the below participants were included in the study: * Participants who are 12 years or older. * Confirmed to have COVID-19 between 01 January 2022 and 31 December 2022. Nirmatrelvir-ritonavir is taken by mouth and is used to treat COVID-19. The study will look at: * the nature of Covid-19 disease. * as well as the experiences of people receiving the nirmatrelvir-ritonavir. This study will help to: * understand what type of patients will need to be admitted to hospitals. * see severe results due to COVID 19 infection. * have more knowledge on the use of nirmatrelvir/ritonavir on COVID-19.
Study Type
OBSERVATIONAL
Enrollment
8,252,912
COVID-19 treatment as per government guidance
No intervention
Pfizer Taiwan
Taipei, Taiwan
Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Required Intensive Care Unit (ICU)
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Required ICU
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Did Not Require ICU
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a diagnosis of COVID-19 that did not require ICU
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Demographical Characteristics of Participants with a diagnosis of COVID-19 that required ICU
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Required Ventillatory Support
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Required Ventillatory Support
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Demographical Characteristics of Participants with a Diagnosis of COVID-19 That Did Not Require Ventillatory Support
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Did Not Require Ventillatory Support
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Had a Fatal Outcome
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Had a Fatal Outcome
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Did Not Have a Fatal Outcome
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Did Not Have a Fatal Outcome
Time frame: 01 January 2021 to 31 December 2021
Cohort 2: Characteristics Associated with Patients Receiving nirmatrelvir/ritonavir vs Patients Not Receiving nirmatrelvir/ritonavir
Time frame: 01 January 2022 to 31 December 2022
Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Required Hospital Admission
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Required Hospital Admission
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Demographics of Participants with a Diagnosis of COVID-19 That Did Not Require Hospital Admission
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Comorbidities of Participants with a Diagnosis of COVID-19 That Did Not Require Hospital Admission
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Incidence Proportion of ICU Admissions Among COVID-19 Patients Requiring Hospitalization Per Age Range
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Clinical Characteristics Associated to ICU Admission Among Hospitalized COVID-19 Patients
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Risk Factors Associated to ICU Admission Among Hospitalized COVID-19 Patients
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Clinical Characteristics Associated to Ventilatory Support Among Hospitalized COVID-19 Patients
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Risk Factors Associated to Ventilatory Support Among Hospitalized COVID-19 Patients
Time frame: 01 January 2021 to 31 December 2021
Cohort 1: Mortality Rate Associated to Ventilatory Support Among Hospitalized COVID-19 Patients
Time frame: 01 January 2021 to 31 December 2021
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cohort 1: Average Length of Stay (LOS) of Hospitalized COVID-19 Patients
Time frame: 01 January 2021 to 31 December 2021
Cohort 2: Incidence for severe COVID-19 Overall
Time frame: 01 January 2022 to 31 December 2022
Cohort 2: Incidence for severe COVID-19 By Risk Group
Time frame: 01 January 2022 to 31 December 2022
Cohort 2: Incidence for severe COVID-19 By Time Period
Time frame: 01 January 2022 to 31 December 2022
Cohort 2: Relative Risk for severe COVID-19 Overall
Time frame: 01 January 2022 to 31 December 2022
Cohort 2: Relative Risk for severe COVID-19 By Risk Group
Time frame: 01 January 2022 to 31 December 2022
Cohort 2: Relative Risk for severe COVID-19 By Time Period
Time frame: 01 January 2022 to 31 December 2022